
Shares of online telehealth company Hims & Hers Health HIMS.N fall 6.7% to $15.51 in premarket trading
Co on Monday forecast Q1 revenue below estimates, citing a $65 million hit from changes in the shipping of weight-loss products for personalized prescriptions
HIMS, which grew rapidly after it offered cheaper compounds of weight-loss drugs, now expects Q1 revenue in the range of $600 million to $625 million, below estimates of $653.11 million, according to data compiled by LSEG
Morningstar sees several uncertainties for HIMS, including the Novo Nordisk litigation, regulatory risks around compounding, and execution risk for new launches and markets
Earlier this month, the FDA said it would take action against HIMS for its $49 copycat weight-loss pill; co was also referred to the Dept of Justice for violation
16 analysts rate the stock "hold" on average; median PT is $22 - data compiled by LSEG
As of last close, stock down 52.23% YTD